Stocklytics Platform
Asset logo for symbol LUNG
Pulmonx
LUNG56
$7.92arrow_drop_down0.62%-$0.05
Asset logo for symbol LUNG
LUNG56

$7.92

arrow_drop_down0.62%
Key Stats
Open$8.07
Prev. Close$8.08
EPS-1.54
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range7.80
8.34
52 Week Range5.67
14.83
Ratios
EPS-1.54
Fundamentals
Payout Ratio-
Industry average yield2.86%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

LUNGarrow_drop_down2.10%
US Healthcare Sectorarrow_drop_down0.42%
US Marketarrow_drop_down0.13%
warning
LUNG / Market
LUNG lose to the US Market which returned -0.13% over the last twenty four hours.
warning
LUNG / Healthcare Sector
LUNG lose to the US Healthcare sector which returned -0.42% over the last twenty four hours.

Pulmonx (LUNG) Statistics

Pulmonx Corp (LUNG) is a leading medical device company focused on providing minimally invasive solutions for patients with severe respiratory conditions. The company's innovative products have helped revolutionize the treatment of conditions such as chronic obstructive pulmonary disease (COPD) and severe emphysema. With a strong commitment to research and development, Pulmonx Corp has established itself as a pioneer in the field of respiratory medicine.

When it comes to valuation metrics, Pulmonx Corp has shown impressive growth. The company's stock has performed well in comparison to the sector, indicating strong investor confidence. Additionally, Pulmonx Corp's revenue per share has been consistently high, reflecting the company's ability to generate substantial earnings. This is further supported by its impressive enterprise to EBITDA ratio, which demonstrates efficient management of operating costs.

add Pulmonx to watchlist

Keep an eye on Pulmonx

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
How has Pulmonx (LUNG) stock's performance compared to its sector and the market over the past year?

Over the past year, Pulmonx (LUNG) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 25.13%, Pulmonx has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 50.53%, it has fallen short of the market average. This comparison highlights Pulmonx's performance relative to both its sector and the overall market over the last year.

help
What is the PE ratio of Pulmonx (LUNG) stock?

The PE ratio for Pulmonx (LUNG) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.

help
What is the EPS of Pulmonx (LUNG) stock?

The Earnings Per Share (EPS) for Pulmonx (LUNG), calculated on a diluted basis, is -$1.54. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.

help
What is the operating margin of Pulmonx (LUNG) stock?

The operating margin for Pulmonx (LUNG) is -77.1%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

help
What is the EBITDA of Pulmonx (LUNG) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Pulmonx (LUNG) is -$58.54M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

help
How much debt does Pulmonx (LUNG) have?

Pulmonx (LUNG) has a total debt of $40.57M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$29.82M.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level